Proton pump inhibitors may enhance the risk of citalopram‐ and escitalopram‐associated sudden cardiac death among patients receiving hemodialysis

Polypharmacy is common in the hemodialysis population and increases the likelihood that patients will be exposed to clinically significant drug–drug interactions. Concurrent use of proton pump inhibitors (PPIs) with citalopram or escitalopram may potentiate the QT‐prolonging effects of these selective serotonin reuptake inhibitors through pharmacodynamic and/or pharmacokinetic interactions.

• Publication year

  2022

• Venue

  Pharmacoepidemiology and Drug Safety

• Publication date

  2022-03-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pds.5428PMID 35285107PMCID PMC9064943
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A systematic review and meta-analysis: effects of glucocorticoids on rheumatoid arthritis and systemic lupus erythematosus.

  2021cited by this paper
• Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association.

  2020cited by this paper
• Medication Reconciliation: The Foundation of Medication Safety for Patients Requiring Dialysis.

  2020influential reference
• End-stage renal disease reduces the expression of drug-metabolizing cytochrome P450s

  2020cited by this paper
• Use of QT Prolonging Medications by Hemodialysis Patients and Individuals Without End‐Stage Kidney Disease

  2020cited by this paper
• Adverse Drug Events in Patients with Chronic Kidney Disease Associated with Multiple Drug Interactions and Polypharmacy

  2020cited by this paper
• Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis.

  2019cited by this paper
• Cardiovascular Outcomes Associated With Clinical Use of Citalopram and Omeprazole: A Nationwide Population‐Based Cohort Study

  2019cited by this paper
• Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes

  2018cited by this paper
• Fluoroquinolones increase the risk of serious arrhythmias

  2017cited by this paper
• Sudden Cardiac Death Among Hemodialysis Patients.

  2017cited by this paper
• Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients

  2016influential reference
• Identifying and Communicating Clinically Meaningful Drug–Drug Interactions

  2016cited by this paper
• Management of Polypharmacy in Dialysis Patients

  2015influential reference
• Case report, aetiology, and treatment of an acquired long-QT syndrome

  2014cited by this paper
• Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update

  2014cited by this paper
• Clinical relevance of the (S)-citalopram-omeprazole interaction in geriatric patients.

  2014cited by this paper
• Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.

  2014cited by this paper
• Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport

  2013cited by this paper
• QT interval and antidepressant use: a cross sectional study of electronic health records

  2013influential reference
• Propensity Score Methods for Confounding Control in Nonexperimental Research

  2013cited by this paper
• Comparative safety of selective serotonin reuptake inhibitors among pediatric users with respect to adverse cardiac events

  2013cited by this paper
• A Comparison of the Risk of QT Prolongation Among SSRIs

  2013cited by this paper
• Evaluation of Six Proton Pump Inhibitors As Inhibitors of Various Human Cytochromes P450: Focus on Cytochrome P450 2C19

  2012cited by this paper
• Assessment of Drug-Drug Interactions among Renal Failure Patients of Nephrology Ward in a South Indian Tertiary Care Hospital

  2012influential reference
• Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers.

  2010cited by this paper
• Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research

  2009cited by this paper
• Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation.

  2007cited by this paper
• Sudden cardiac death in nephrology: focus on acquired long QT syndrome.

  2006cited by this paper
• The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects.

  2005cited by this paper
• Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities.

  2004cited by this paper
• Evaluating medication effects outside of clinical trials: new-user designs.

  2003cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper

• Enhanced CYP2C19-mediated drug-drug interaction risk with escitalopram in geriatric populations

  2026cites this paper
• QT-Prolonging Medications: Prevalence of Use and Associated Risks in CKD.

  2025cites this paper
• A Practical Primer on How to Detect and Treat Depression in CKD.

  2025cites this paper
• Citalopram & escitalopram: Mechanisms of cardiotoxicity, toxicology predisposition and risks of use in geriatric & hemodialysis populations

  2024cites this paper
• Use of Sensitivity Analyses to Assess Uncontrolled Confounding from Unmeasured Variables in Observational, Active Comparator Pharmacoepidemiologic Studies: A Systematic Review.

  2024cites this paper
• Prescription and Dispensation of QT-Prolonging Medications in Individuals Receiving Hemodialysis

  2024cites this paper
• Evaluation of Appropriate Use of Proton Pump Inhibitors in Non-critically Ill Patients in Tertiary Medical Center: A Retrospective Study.

  2024cites this paper
• Ondansetron and the Risk of Sudden Cardiac Death among Individuals Receiving Maintenance Hemodialysis

  2024cites this paper
• The Association of Proton Pump Inhibitors and QT Interval Prolongation in Critically Ill Patients

  2023cites this paper
• Hypocalcemia: a cardiovascular risk factor coming of age?

  2023cites this paper
• Guidelines on optimizing the use of proton pump inhibitors: PPI stewardship

  2023cites this paper